LinkedIn
WebsiteIntroduction
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) is a medical diagnostics company headquartered in Acton, Massachusetts. Its Symphony™ platform integrates traditional ELISA methodology with advances in nanotechnology and microfluidics to facilitate near-patient biomarker detection. Symphony is designed to provide quantitative clinical chemistry results in a “sample-to-result” format without further technician intervention, supporting triage and acute-care decision-making.
Corporate Structure
Bluejay Diagnostics operates within the Medical Equipment Manufacturing industry. According to its LinkedIn profile, the company employs between 11 and 50 people. Founded on March 20, 2015, by Svetlana Dey and Indraneil Dey, the company is headquartered in Acton, MA. As a publicly traded entity, it adheres to U.S. Securities and Exchange Commission reporting standards.
Biomarker detection by National Cancer Institute
Recent Developments
On April 7, 2025, Bluejay Diagnostics completed a warrant inducement transaction, generating approximately US$3.7 million in gross proceeds to support ongoing operations and product development. Eight days later, on April 15, 2025, the company announced acceptance of an abstract on the Symphony IL-6 Test for presentation at the Society of Academic Emergency Medicine Annual Meeting (May 13–16, 2025) in Philadelphia. In a mid-year business and corporate update dated June 3, 2025, Bluejay reviewed progress on its clinical programs and outlined near-term milestones. Subsequent SEC filings include a Form 10-Q for the quarter ended June 30, 2025 (filed August 7, 2025), an 8-K disclosing corporate governance items (filed August 11, 2025), and an 8-K under Item 8.01 reporting other significant events (filed August 15, 2025).
Financial and Strategic Analysis
As of October 7, 2025, BJDX shares closed at US$1.99, reflecting a 28.39 percent increase from the prior session, on a volume of 15,073,913 shares. The company’s market capitalization is approximately US$2.31 million. According to third-party data, the stock trades near the bottom of its 52-week range and below its 200-day simple moving average.
| Metric | Value |
|---|---|
| Stock Price (2025-10-07) | US$1.99 |
| Change (since prior close) | +28.39 percent |
| Volume | 15,073,913 |
| Market Capitalization | ~US$2.31 million |
| Net Income (TTM) | –US$7.72 million |
| Net Income (Q2 2025) | –US$1.96 million |
| EPS (TTM) | –US$114.19 |
| EPS (Q2 2025) | –US$1.41 |
Strategically, Bluejay focuses on point-of-care applications in the infectious disease, inflammation, and oncology markets. By reducing test complexity and removing the requirement for highly trained laboratory staff, Symphony may enable smaller clinics, long-term acute care facilities, and resource-constrained hospitals to adopt near-patient testing. Continued product development, efforts for regulatory clearance, and additional financing will be important for advancing commercial deployment.
Market Position and Industry Context
Bluejay Diagnostics competes in the Health Technology and Medical Specialties sectors. Its Symphony platform targets a segment of near-patient testing, where rapid turnaround and cost efficiency are significant factors. Established diagnostic companies and emerging point-of-care innovators compose the competitive landscape, while reimbursement dynamics and regulatory approval processes present ongoing considerations.
tl;dr
• On April 7, 2025, Bluejay Diagnostics closed a US$3.7 million warrant inducement transaction.
• On April 15, 2025, an abstract on the Symphony IL-6 Test was accepted for presentation at SAEM’s annual meeting.
• On June 3, 2025, the company issued a mid-year business and corporate update outlining clinical and regulatory milestones.
• Q2 financials (filed August 7, 2025) show a net loss of US$1.96 million and EPS of –US$1.41.
• Future outlook is dependent on Symphony’s regulatory clearance, additional capital raises, and market adoption in critical-care settings.
